Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ketoprofen
Drug ID BADD_D01231
Description Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Indications and Usage For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
Marketing Status Prescription; Discontinued
ATC Code M01AE03; M02AA10
DrugBank ID DB01009
KEGG ID D00132
MeSH ID D007660
PubChem ID 3825
TTD Drug ID D0W9WF
NDC Product Code 49452-3917; 68981-031; 82348-102; 0276-0504; 12660-0006; 69336-127; 12854-516; 43235-0010; 63275-9996; 51927-0057; 76465-0001; 51927-0025; 51552-0307; 63187-018; 38779-0078; 51927-0231; 0395-8056; 45865-485; 38779-3039; 49452-3924; 0378-8200; 79572-019; 51604-0011
Synonyms Ketoprofen | Benzoylhydratropic Acid | 2-(3-Benzoylphenyl)propionic Acid | Profenid | Alrheumum | Orudis | 19,583 RP | RP, 19,583 | RP-19583 | RP 19583 | RP19583 | Alrheumat
Chemical Information
Molecular Formula C16H14O3
CAS Registry Number 22071-15-4
SMILES CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Gastrointestinal toxicityTumor necrosis factorP01375T2017811991627; 11131303; 11930903; 11230998
Gastrointestinal toxicityGlutathione reductase, mitochondrialP00390T3080311991627; 11131303; 11930903; 11230998
Toxic dilatation of intestineGlutathione reductase, mitochondrialP00390T3080311991627; 11131303; 11930903; 11230998
Toxic dilatation of intestineTumor necrosis factorP01375T2017811991627; 11131303; 11930903; 11230998
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.06.0080.008278%Not Available
Vomiting07.01.07.0030.091057%
Water intoxication19.07.03.004; 14.05.06.004; 05.03.03.0030.008278%Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.0090.008278%
Tubulointerstitial nephritis20.05.02.0020.016556%Not Available
Joint range of motion decreased15.01.02.0060.008278%
Hypoacusis04.02.01.006--
Balance disorder17.02.02.0070.008278%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Pruritus generalised23.03.12.0030.037250%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.01.0150.012417%Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Toxic skin eruption23.03.05.003; 10.01.01.0080.008278%Not Available
Staphylococcal infection11.02.05.0020.008278%Not Available
Vasodilation procedure25.03.01.001--Not Available
Application site discolouration23.03.03.023; 12.07.01.030; 08.02.01.030--Not Available
Blood alkaline phosphatase increased13.04.02.0040.008278%
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.0050.008278%
Libido disorder21.03.02.006; 19.08.03.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Disease recurrence08.01.03.0500.008278%Not Available
Occult blood13.05.02.003--Not Available
Urinary tract pain20.02.03.013--
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages